Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (Nasdaq: ECOR) is a commercial-stage bioelectronic medicine and wellness company that regularly issues news on its non-invasive neuromodulation technologies, prescription therapies, and wellness and performance devices. This news feed aggregates company press releases, clinical study announcements, reimbursement developments, corporate updates, and other disclosures directly related to electroCore.
Readers can follow updates on electroCore’s prescription products, including gammaCore non-invasive vagus nerve stimulation (nVNS) and the Quell neurostimulator for chronic pain syndromes, as well as its handheld Truvaga and TAC-STIM devices for general wellness and human performance. News items have covered peer-reviewed studies on gammaCore in persistent post-concussion symptoms, controlled trials of TAC-STIM in active-duty Air Force trainees, and recognition of Truvaga Plus in consumer-focused awards.
The ECOR news stream also includes financial and corporate information such as quarterly results, revenue trends, private placements, participation in investor conferences, and changes to the board of directors and executive team. Regulatory and market access milestones, like reimbursement decisions for gammaCore Sapphire in Belgium, appear alongside product and clinical updates.
Investors, clinicians, and individuals interested in bioelectronic medicine can use this page to review electroCore’s historical and recent announcements in one place. For deeper analysis of any item, users can combine these news releases with the company’s SEC filings and other official documents accessible through related sections of the platform.
electroCore (Nasdaq: ECOR) announced a research study with Acacia Clinics and the Vagus Nerve Society testing gammaCore Sapphire as an adjunctive treatment for PTSD symptoms.
The prospective study will enroll up to 40 adults (18–70) over an anticipated 10-month period. The primary safety measure is incidence of treatment-related significant adverse events (SAEs); the primary efficacy endpoint is change from baseline in CAPS-5 total score at 12 weeks (vs baseline/4-week run-in). Secondary outcomes include change in PCL-5 and Clinical Global Index (CGI) at 12 weeks. The study is led by Danielle DeSouza MSc, PhD, sponsored by the Vagus Nerve Society, with electroCore providing an educational grant and devices.
electroCore (Nasdaq: ECOR) reported preliminary unaudited full-year 2025 results and guidance: record revenue expected at $31.8–$32.0 million, representing ~26% growth versus 2024 ($25.2M). Fourth-quarter 2025 revenue is anticipated at $9.0–$9.2 million, about 30% growth versus Q4 2024. The company ended 2025 with approximately $11.6 million in cash, cash equivalents, and marketable securities, down from ~$13.2 million at September 30, 2025. electroCore described these figures as preliminary unaudited guidance and plans a full operational and financial update on its Q4 and FY2025 earnings call in March 2026.
electroCore (Nasdaq: ECOR) announced a peer‑reviewed study showing its TAC‑STIM™ transcutaneous vagal nerve stimulation (tVNS) device improved mood, task performance, and learning in 70 active‑duty U.S. Air Force trainees.
Key results include statistically significant reductions in distress (p<0.001), higher perceived ability (p=0.020), increased energy (p=0.002), and objective performance gains in intelligence tasks and instructor assessments (group main effect p=0.020). Findings were sustained across four days and will be presented at AHFE2025 on December 8, 2025.
electroCore (Nasdaq: ECOR) announced that company management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 20, 2025 at The Westin NY Grand Central Hotel.
Management will host one-on-one meetings throughout the day. Investors seeking a meeting should contact their Canaccord Genuity sales representative or email electroCore Investor Relations at ecor@fnkir.com.
electroCore (Nasdaq: ECOR) reported record Q3 2025 net sales of $8.7 million, up 33% year-over-year, and year-to-date net sales of $22.8 million, up 26% versus the first nine months of 2024. Total cash was $13.2 million at September 30, 2025. Management cited strong prescription growth in the VA (gammaCore +16% in VA) and Truvaga record quarterly sales of $1.7 million; Quell Fibromyalgia contributed $530,000 in VA revenues and $595,000 of product sales in Q3. GAAP net loss was $3.4 million (loss per share $0.40); adjusted EBITDA net loss was $2.0 million. The company raised full-year 2025 revenue guidance to $31.5–$32.5 million and expects to reach $12.0 million quarterly revenue and first positive adjusted EBITDA in H2 2026.
electroCore (Nasdaq: ECOR) will report third quarter results for the period ended September 30, 2025 after market close on Wednesday, November 5, 2025. Management will host a results webinar on November 5, 2025 at 4:30 PM EST to review the financial results and answer questions.
Investors can join via dial-in (646) 931-3860, Webinar ID 822 9598 1338, passcode 454695, or register using the provided registration link to participate and ask questions.
electroCore (NASDAQ: ECOR) announced on October 3, 2025 that Jennifer Hayes will join the company as Vice President, Human Resources and Employee Success, effective October 6, 2025.
The Compensation Committee granted 10,000 restricted stock units (RSUs) as an inducement under NASDAQ Listing Rule 5635(c)(4). The RSUs vest one-third on each of the first, second and third anniversaries of the grant, subject to continued employment, and will be settled in shares of common stock upon vesting.
electroCore (Nasdaq: ECOR) announced promising results from a peer-reviewed study published in Frontiers in Neurology demonstrating the effectiveness of their gammaCore® non-invasive vagus nerve stimulation (nVNS) device in treating mild traumatic brain injury (mTBI) symptoms.
The study, involving 102 patients, showed significant improvements across multiple symptom categories when gammaCore was used as an adjunctive treatment. 34% of patients reported meaningful improvement in at least half of their persistent symptoms, with benefits observed regardless of time since injury. The treatment showed effectiveness in 16 out of 22 symptom categories, including post-traumatic headache, dizziness, and depression, with no device-related adverse events reported.
electroCore (NASDAQ:ECOR) has secured a significant regulatory milestone as its gammaCore™ Sapphire (nVNS) device received reimbursement approval from Belgium's National Institute for Health and Disability Insurance (RIZIV/INAMI). The coverage, effective October 1, 2025, will provide Belgian patients suffering from cluster headaches access to this bioelectronic treatment.
The approval was achieved through collaboration with Silvert Medical, electroCore's distribution partner in Belgium, and is supported by strong clinical evidence demonstrating the therapy's efficacy and cost-effectiveness. Prof. Paemeleire from Ghent University Hospital's Headache Clinic endorsed the decision, highlighting the benefits of non-invasive vagus nerve stimulation for patients.
[ "Secured reimbursement approval in Belgium, expanding market access", "Partnership with established distributor Silvert Medical for market penetration", "Strong clinical evidence supporting therapy efficacy and cost-effectiveness", "Strategic position in central Europe for potential expansion to neighboring countries" ]electroCore (Nasdaq: ECOR) announced that its Truvaga™ Plus device has been awarded "Best Relaxation Gadget" in Esquire's 2025 Sleep Awards. The handheld vagus nerve stimulation (nVNS) device was selected by Esquire's editors after extensive testing, recognized for its ability to promote relaxation and better sleep through two-minute sessions.
The device stands out for its drug-free approach to calming the nervous system, reducing stress, and enhancing sleep quality. This recognition in Esquire's annual Sleep Awards, which highlights the most effective sleep and recovery solutions, serves as third-party validation for consumers seeking alternative sleep improvement methods.
FAQ
What is the current stock price of Electrocore (ECOR)?
What is the market cap of Electrocore (ECOR)?
